FDA chief says criticism for misrepresenting convalescent plasma stats is warranted | The Hill: Healthcare Policy

The head of the Food and Drug Administration (FDA) on Monday said criticism for his praise of convalescent plasma treatment was warranted, but denied the decision to authorize the emergency use of the treatment for COVID-19 patients was politically...